HLS Therapeutics Inc. (HLS) Earnings Call Transcripts
HLS Therapeutics Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 Fiscal 2026, HLS Therapeutics reported revenues of $12.9 million, a 2% increase year-over-year, driven primarily by a 15% rise in Vascepa net sales. Adjusted EBITDA came in at $3.5 million, down from $3.8 million in the prior year, as the company increased investments related to the NILEMDO launch. Management reaffirmed its guidance for 2026, projecting revenues between $56 million and $60 million, with adjusted EBITDA of $18.5 million to $21 million, indicating a focus on growth despite initial launch costs.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $12.9 million (inline) |
| Adjusted EBITDA | $3.5 million (miss) |
| Vascepa Net Sales | $4.8 million (positive) |
| Clozaril Net Sales | $7.8 million (inline) |
| Cash from Operations | $6.4 million (positive) |
| Net Debt | $31.9 million (positive) |
Guidance from management
Management reaffirmed its 2026 revenue guidance of $56 million to $60 million and adjusted EBITDA of $18.5 million to $21 million, indicating confidence in achieving growth despite launch-related expenses.
What management said
Great. Thank you. So thanks, everyone, for participating, especially I know there's a long holiday weekend coming up in Canada. So I appreciate that and wish everyone a happy holiday weekend. And we look forward to continuing to report on our progress in the coming quarters and speaking again to you all very soon. Take care.
What analysts pressed on
Analysts expressed concerns regarding the sustainability of Vascepa's growth and the potential impact of contracting dynamics on Clozaril. There were also inquiries about the effectiveness of the NILEMDO launch strategy and how it would influence overall company performance moving forward.
Main topics on the call
- Vascepa Sales Growth — Vascepa net sales increased by 15% year-over-year, reaching $4.8 million in Q1. Management noted, "the leadership and staffing changes, along with the commercial strategy that we put in place last year are having the des...
- NILEMDO Launch Progress — NILEMDO had a successful launch in April, with nearly CAD 0.25 million worth of shipments and full coverage from major private payers. Management stated, "we're pleased with how this launch is progressing," indicating st...
- Clozaril Performance — Clozaril's performance was in line with expectations, with net sales of $7.8 million, down from $8.2 million year-over-year. Management highlighted a return to patient growth in Ontario as a positive sign for future perf...
- Financial Position Improvement — HLS reduced its net debt by 52% over two years, ending Q1 with $31.9 million in net debt. Cash from operations increased by 80% year-over-year, reflecting operational improvements and lower interest expenses.
Read the full HLS Therapeutics Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About HLS Therapeutics Inc.
HLS Therapeutics Inc. (HLS) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on TSX and is based in CA. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 54 calls on record spanning February 26, 2020 to June 26, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 54 HLS Therapeutics Inc. earnings call transcripts on record, spanning February 26, 2020 to June 26, 2026. Based on this history, HLS Therapeutics Inc. reports quarterly. The most recent call on file is dated June 26, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- HLS
- Exchange
- TSX
- Country
- CA
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 54
- First call
- February 26, 2020
- Most recent
- June 26, 2026
- Reporting cadence
- quarterly